Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2935109 | International Journal of Cardiology | 2007 | 4 Pages |
Abstract
Heart valve bioprostheses can undergo early post-implantation changes, including pannus and thrombus, which may be hastened by the presence of a left ventricular assist device (LVAD). We report the case of a 21 year-old male who was diagnosed with dilated cardiomyopathy and severe aortic insufficiency, and had his aortic valve replaced with a #25 BioPhysio® valve (currently in clinical trials — Edwards Life Sciences, Irvine, CA, USA). His symptoms of congestive heart failure continued to worsen, and he received a Novacor® LVAD (WorldHeart, Oakland, CA, USA), and subsequently, an orthotopic heart transplantation. The relevant pathologies of the heart, BioPhysio® valve (in place for 4.5 months), and Novacor® device are presented.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jagdish Butany, Shaun W. Leong, Vivek Rao, Michael A. Borger, Tirone E. David, Kristopher S. Cunningham, Loretta Daniel,